From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis

Biomolecules. 2024 Aug 28;14(9):1080. doi: 10.3390/biom14091080.

Abstract

Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus. EoE shares a common pathogenetic mechanism with other chronic disorders pertaining to the type 2 inflammatory spectrum, such as atopic dermatitis (AD), allergic rhinitis (AR), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The recent advancements in EoE pathogenesis understanding have unveiled new molecular targets implied within the "atopic march" picture as well as specific to EoE. These discoveries have led to the clinical evaluation of several novel drugs (monoclonal antibodies and immune modulators), specifically aimed at the modulation of Th2 inflammation. In this comprehensive review, we have focused on the subtle mechanisms of type 2 inflammatory disorders, highlighting the similarities and differences with EoE, taking a deeper look into the evolving field of biologic therapies, already approved or under current investigation.

Keywords: EoE; atopic march; atopy; biologics; eosinophilic esophagitis; type 2 inflammation.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / immunology
  • Dermatitis, Atopic / pathology
  • Eosinophilic Esophagitis* / drug therapy
  • Eosinophilic Esophagitis* / pathology
  • Humans
  • Inflammation / drug therapy
  • Th2 Cells* / immunology
  • Th2 Cells* / metabolism

Substances

  • Antibodies, Monoclonal

Grants and funding

This research received no external funding.